Results 121 to 130 of about 3,293,378 (262)

Does Isoniazid Chemoprophylaxis Increase the Frequency of Hepatotoxicity in Patients Receiving Anti-TNF -α Agent with a Disease Modifying Antirheumatic Drug?

, 2014
Döndü Üsküdar Cansu, Sabri Güncan, Nazife Şule Yaşar Bilge, Timuçin Kaşifoğlu, Cengiz Korkmaz   +4 more
openalex   +3 more sources

A Causal Association Between Drug Use and Cognitive Impairment: A Two-Sample Mendelian Randomization Study. [PDF]

Brain Behav
Yan B, Chen Z, Yang D.
europepmc   +1 more source

Adoption of new treatment options in non-systemic juvenile idiopathic arthritis (JIA) in clinical practice. [PDF]

Pediatr Rheumatol Online J
Lamers HC, Van Nieuwenhove E, Vastert SJ, Jansen MHA, van Royen-Kerkhof A, Swart JF, de Roock S.   +6 more
europepmc   +1 more source

Prevalence and risk factors of difficult-to-treat axial spondyloarthritis: Real-life evidence from the BioSTaR database. [PDF]

Clin Rheumatol
Bodur H, Ataman Ş, Yurdakul FG, Gürer G, Akgün K, İnceoğlu LA, Sunar İ, Akgül Ö, Sezer İ, Çapkın E, Rezvani A, Yağcı İ, Duruöz MT, Çay HF, Çevik R, Göğüş F, Kamanlı A, Ecesoy H, Güler T, Şahin N, Cengiz G, Melikoğlu MA.   +21 more
europepmc   +1 more source

Leflunomide-induced pancytopenia and agranulocytosis resulting in septic shock: A case report. [PDF]

Medicine (Baltimore)
Chang WH, Chien SC, Hu TY.
europepmc   +1 more source

Predicting the progression of difficult-to-treat rheumatoid arthritis by a machine learning scoring system, from the FIRST registry. [PDF]

RMD Open
Ueno M, Sonomoto K, Tanaka H, Nagayasu A, Aritomi T, Miyagawa I, Kubo S, Miyazaki Y, Todoroki Y, Satoh-Kanda Y, Fujita Y, Sakai H, Nakayamada S, Tanaka Y.   +13 more
europepmc   +1 more source

Protocol for DESCIDE-RD: Determining Effectiveness of Shared Decision Making in Drug Therapy Selection for Rheumatic Diseases. [PDF]

J Korean Med Sci
Choi SR, Cho SK, Nam B, Park HR, Lee SB, Ko HR, Choi YJ, Nam E, Lee SW, Yoon S, Sung YK, and on behalf of DESCIDE-RD Investigators.   +11 more
europepmc   +1 more source

On-Label Treatment Persistence Through 24 Months Among Patients with Active Psoriatic Arthritis Initiating Guselkumab or Subcutaneous Tumor Necrosis Factor Inhibitors. [PDF]

Rheumatol Ther
Mease PJ, Walsh JA, Fitzgerald TP, Chakravarty SD, Adamson E, Emond B, Rossi C, Schwartzbein S, Yokoji K, Wang Y, Lefebvre P, Pilon D, Singla S, Merola JF.   +13 more
europepmc   +1 more source

A Practical Procedure for the Synthesis of Esonarimod, (R,S)-2-Acetylthiomethyl-4-(4-methylphenyl)-4-oxobutanoic Acid, an Antirheumatic Agent. (Part 1).

, 2002
Toshiya Noguchi, Akira Onodera, Kazuyuki Tomisawa, Sadakazu Yokomori   +3 more
openalex   +2 more sources

Antirheumatic Agents. III. Novel Methotrexate Derivatives Bearing an Indoline Ring and a Modified Ornithine or Glutamic Acid.

, 1997
Hirotaka Matsuoka, Naoki Kato, Naoto Ohi, Ken‐ichi Miyamoto, Masahiko Mihara, Y. Takeda   +5 more
openalex   +2 more sources